Chronic gastritis and small intestinal bacterial overgrowth: Common comorbidities
https://doi.org/10.21518/ms2025-428
Abstract
Introduction. Helicobacter pylori colonization significantly affects not only the gastric microenvironment, but also the intestinal microbiota. Numerous studies have shown that proton pump inhibitors (PPIs) can alter the intestinal flora of patients. This article examines the available data on the relationship between gastritis, Helicobacter pylori (Hp) infection, and small intestinal bacterial overgrowth (SIBO).
Aim. To compare the level of comorbidity and severity of SIBO in patients with chronic gastritis of various origin – Hp-positive (Hp+) and Hp-negative (Hp-).
Materials and methods. In our study, we examined the medical data of 122 patients (24 men and 98 women) aged 20 to 60 years (mean age 51 years). Of these, 62 had Hp+ gastritis and 60 had Hp-. All patients also underwent lactulose hydrogen breath testing to detect SIBO.
Results and discussion. SIBO was diagnosed in half of the patients (32 patients, 51.6%) in the Hp+ group and in one-third of the patients with Hp-gastritis (18 patients, 30%) (p ≤ 0.05). In our study, repeated testing didn’t detect SIBO after anti-Helicobacter therapy in patients from the Hp+ group.
Conclusions. The patients on regular PPI therapy, with Hp+ and Hp-gastritis and symptoms of intestinal indigestion should undergo diagnostic testing for SIBO. Hp eradication in patients with gastritis combined with SIBO contributes to the successful small intestine decontamination.
About the Authors
E. Yu. Plotnikova
Kemerovo State Medical University
Russian Federation
Russian Federation
Ekaterina Yu. Plotnikova - Dr. Sci. (Med.), Professor, Professor of the Department of Postgraduate Training and Nursing, Head of the Course of Clinical Gastroenterology, Kemerovo State Medical University.
22a, Voroshilov St., Kemerovo, 650056
A. O. Kutsaeva
Clinical Consulting and Diagnostic Center named after I.A. Kolpinsky
Russian Federation
Russian Federation
Alena O. Kutsaeva - Gastroenterologist, Clinical Consulting and Diagnostic Center named after I.A. Kolpinsky.
53/1, Oktyabrsky Ave., Kemerovo, 650066
M. A. Nikonorova
Altai State Medical University
Russian Federation
Russian Federation
Marina A. Nikonorova - Dr. Sci. (Med.), Associate Professor, Professor of the Department of Infectious Diseases with a Course of Continuing Professional Education, Altai State Medical University.
40, Lenin Ave., Barnaul, 656038
References
1. Perez-Lopez A, Behnsen J, Nuccio SP, Raffatellu M. Mucosal immunity to pathogenic intestinal bacteria. Nat Rev Immunol. 2016;16(3):135–148. https://doi.org/10.1038/nri.2015.17.
2. Bushyhead D, Quigley EM. Small Intestinal Bacterial Overgrowth. Gastroenterol Clin North Am. 2021;50(2):463–474. https://doi.org/10.1016/j.gtc.2021.02.008.
3. Bushyhead D, Quigley EMM. Small Intestinal Bacterial Overgrowth – Pathophysiology and Its Implications for Definition and Management. Gastroenterology. 2022;163(3):593–607. https://doi.org/10.1053/j.gastro.2022.04.002.
4. Gandhi A, Shah A, Jones MP, Koloski N, Talley NJ, Morrison M, Holtmann G. Methane positive small intestinal bacterial overgrowth in inflammatory bowel disease and irritable bowel syndrome: A systematic review and meta-analysis. Gut Microbes. 2021;13(1):1933313. https://doi.org/10.1080/19490976.2021.1933313.
5. Gurusamy SR, Shah A, Talley NJ, Koloski N, Jones MP, Walker MM et al. Small Intestinal Bacterial Overgrowth in Functional Dyspepsia: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2021;116(5):935–942. https://doi.org/10.14309/ajg.0000000000001197.
6. El Kurdi B, Babar S, El Iskandarani M, Bataineh A, Lerch MM, Young M, Singh VP. Factors That Affect Prevalence of Small Intestinal Bacterial Overgrowth in Chronic Pancreatitis: A Systematic Review, Meta-Analysis, and Meta-Regression. Clin Transl Gastroenterol. 2019;10(9):e00072. https://doi.org/10.14309/ctg.0000000000000072.
7. Maslennikov R, Pavlov C, Ivashkin V. Small intestinal bacterial overgrowth in cirrhosis: systematic review and meta-analysis. Hepatol Int. 2018;12(6):567–576. https://doi.org/10.1007/s12072-018-9898-2.
8. Gudan A, Jamioł-Milc D, Hawryłkowicz V, Skonieczna-Żydecka K, Stachowska E. The Prevalence of Small Intestinal Bacterial Overgrowth in Patients with Non-Alcoholic Liver Diseases: NAFLD, NASH, Fibrosis, Cirrhosis – A Systematic Review, Meta-Analysis and Meta-Regression. Nutrients. 2022;14(24):5261. https://doi.org/10.3390/nu14245261.
9. Feng X, Li XQ. The prevalence of small intestinal bacterial overgrowth in diabetes mellitus: a systematic review and meta-analysis. Aging. 2022;14(2):975–988. https://doi.org/10.18632/aging.203854.
10. Feng X, Li XQ, Jiang Z. Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review and meta-analysis. Clin Rheumatol. 2021;40(8):3039–3051. https://doi.org/10.1007/s10067-020-05549-8.
11. Li X, Feng X, Jiang Z, Jiang Z. Association of small intestinal bacterial overgrowth with Parkinson’s disease: a systematic review and meta-analysis. Gut Pathog. 2021;13(1):25. https://doi.org/10.1186/s13099-021-00420-w.
12. Patel SM, Young MC. The Identification and Management of Small Intestinal Bacterial Overgrowth: A Functional Medicine Approach. Phys Med Rehabil Clin N Am. 2022;33(3):587–603. https://doi.org/10.1016/j.pmr.2022.04.003.
13. Pimentel M, Saad RJ, Long MD, Rao SSC. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am J Gastroenterol. 2020;115(2):165–178. https://doi.org/10.14309/ajg.0000000000000501.
14. Salvatori S, Marafini I, Laudisi F, Monteleone G, Stolfi C. Helicobacter pylori and Gastric Cancer: Pathogenetic Mechanisms. Int J Mol Sci. 2023;24(3):2895. https://doi.org/10.3390/ijms24032895.
15. Fujimori S. Progress in elucidating the relationship between Helicobacter pylori infection and intestinal diseases. World J Gastroenterol. 2021;27(47):8040–8046. https://doi.org/10.3748/wjg.v27.i47.8040.
16. Lu D, Wang M, Ke X, Wang Q, Wang J, Li D et al. Association Between H. pylori Infection and Colorectal Polyps: A Meta-Analysis of Observational Studies. Front Med. 2022;8:706036. https://doi.org/10.3389/fmed.2021.706036.
17. Zuo Y, Jing Z, Bie M, Xu C, Hao X, Wang B. Association between Helicobacter pylori infection and the risk of colorectal cancer: A systematic review and meta-analysis. Medicine. 2020;99(37):e21832. https://doi.org/10.1097/MD.0000000000021832.
18. Wang C, Yin Y, Wang L, Guo X, Liu L, Qi X. Association between Helicobacter pylori infection and irritable bowel syndrome: a systematic review and meta-analysis. Postgrad Med J. 2023;99(1169):166–175. https://doi.org/10.1136/postgradmedj-2021-141127.
19. Chen CC, Liou JM, Lee YC, Hong TC, El-Omar EM, Wu MS. The interplay between Helicobacter pylori and gastrointestinal microbiota. Gut Microbes. 2021;13(1):1909459. https://doi.org/10.1080/19490976.2021.1909459.
20. Liao L, Su BB, Xu SP. Helicobacter pylori infection and small intestinal bacterial overgrowth: a systematic review and meta-analysis. BMC Microbiol. 2023;23(1):386. https://doi.org/10.1186/s12866-023-03063-w.
21. Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(5):483–490. https://doi.org/10.1016/j.cgh.2012.12.011.
22. Malfertheiner P, Kandulski A, Venerito M. Proton-pump inhibitors: understanding the complications and risks. Nat Rev Gastroenterol Hepatol. 2017;14(12):697–710. https://doi.org/10.1038/nrgastro.2017.117.
23. Perry IE, Sonu I, Scarpignato C, Akiyama J, Hongo M, Vega KJ. Potential proton pump inhibitor-related adverse effects. Ann N Y Acad Sci. 2020;1481(1):43–58. https://doi.org/10.1111/nyas.14428.
24. Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology. 2010;139(4):1115–1127. https://doi.org/10.1053/j.gastro.2010.08.023.
25. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006;355(17):1834–1836. https://doi.org/10.1056/NEJMc066308.
26. Vesper BJ, Jawdi A, Altman KW, Haines GK 3rd, Tao L, Radosevich JA. The effect of proton pump inhibitors on the human microbiota. Curr Drug Metab. 2009;10(1):84–89. https://doi.org/10.2174/138920009787048392.
27. Hoskins J, Alborn WE Jr, Arnold J, Blaszczak LC, Burgett S, DeHoff BS et al. Genome of the bacterium Streptococcus pneumoniae strain R6. J Bacteriol. 2001;183(19):5709–5717. https://doi.org/10.1128/JB.183.19.5709-5717.2001.
28. Su T, Lai S, Lee A, He X, Chen S. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. J Gastroenterol. 2018;53(1):27–36. https://doi.org/10.1007/s00535-017-1371-9.
29. Durán-Rosas C, Priego-Parra BA, Morel-Cerda E, Mercado-Jauregui LA, Aquino-Ruiz CA, Triana-Romero A et al. Incidence of Small Intestinal Bacterial Overgrowth and Symptoms After 7 Days of Proton Pump Inhibitor Use: A Study on Healthy Volunteers. Dig Dis Sci. 2024;69(1):209–215. https://doi.org/10.1007/s10620-023-08162-2.
30. Tian L, Huang C, Fu W, Gao L, Mi N, Bai M et al. Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiota. Front Pharmacol. 2023;14:1217306. https://doi.org/10.3389/fphar.2023.1217306.
31. Plotnikova EYu, Kutsaeva AO, Sukhikh AS, Baranova EN, Sinkov MA, Nikonorova MA. Chronic morphologically verified gastritis, variants of course. Farmateka. 2025;32(4):32–41. (In Russ.) https://doi.org/10.18565/pharmateca.2025.4.32-41.
32. Rezaie A, Buresi M, Lembo A, Lin H, McCallum R, Rao S et al. Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus. Am J Gastroenterol. 2017;112(5):775–784. https://doi.org/10.1038/ajg.2017.46.
Review
For citations:
Plotnikova EY, Kutsaeva AO, Nikonorova MA. Chronic gastritis and small intestinal bacterial overgrowth: Common comorbidities. Meditsinskiy sovet = Medical Council. 2025;(15):85-89. (In Russ.) https://doi.org/10.21518/ms2025-428
Views:
19
Email this article 